119-s1774

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 1774 Introduced in Senate

    (IS) ]

<DOC>

119th CONGRESS
 1st Session
 S. 1774

 To amend title 5, United States Code, to provide that certain 
 treatments may not be covered under the health insurance program 
 carried out under chapter 89 of that title, and for other purposes.

_______________________________________________________________________

 IN THE SENATE OF THE UNITED STATES

 May 15, 2025

 Mr. Risch (for himself, Ms. Lummis, Mr. Ricketts, and Mr. Cramer) 
introduced the following bill; which was read twice and referred to the 
 Committee on Homeland Security and Governmental Affairs

_______________________________________________________________________

 A BILL

 To amend title 5, United States Code, to provide that certain 
 treatments may not be covered under the health insurance program 
 carried out under chapter 89 of that title, and for other purposes.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``Protecting Minors in Federal Health 
Plans Act''.

SEC. 2. PROHIBITIONS ON FEHB COVERAGE FOR CERTAIN TREATMENT.

    (a) In General.--

Section 8902 of title 5, United States Code, is 
amended by adding at the end the following:
 ``

    (q)

    (1) In this subsection, the term `gender-affirming care or 
service'--
 ``
        (A) means a medical intervention designed to treat gender 
 dysphoria;
 ``
        (B) includes hormone therapy, the use of puberty 
 blockers, and any surgical procedure aimed at gender 
 transition; and
 ``
            (C) notwithstanding subparagraphs
        (A) and
        (B) , does not 
 include--
 ``
            (i) a service provided to an individual with a 
 medically verifiable disorder of sexual development, 
 including an individual with an irresolvable and 
 ambiguous external sex characteristic, including an 
 individual born with--
 ``
            (I) 46 XY chromosomes and under-
 virilization;
 ``
            (II) 46 XX chromosomes and virilization; 
 or
 ``
            (III) both ovarian and testicular tissue;
 ``
            (ii) a service provided to treat a disorder 
 diagnosed by a physician in which the physician has 
 determined through genetic or biochemical testing that 
 the applicable individual has abnormal (or otherwise 
 inconsistent with typical male or female 
 characteristics)--
 ``
            (I) sex chromosome structure;
 ``
            (II) sex steroid hormone production; or
 ``
            (III) sex steroid hormone action;
 ``
            (iii) the treatment of any infection, injury, 
 disease, or disorder that has been caused or worsened 
 by a medical intervention described in subparagraph
        (A) , without regard to whether that intervention--
 ``
            (I) was performed in compliance with 
 State or Federal law; or
 ``
            (II) was covered under a contract under 
 this chapter, as of the date on which the 
 intervention was performed;
 ``
            (iv) any procedure that--
 ``
            (I) is performed to address a physical 
 disorder, injury, or illness that, as certified 
 by a physician, poses an imminent risk of death 
 or impairment of major bodily function; and
 ``
            (II) is not performed for the purpose of 
 gender transition or to alleviate 
 psychological, physical, or mental distress 
 relating to gender;
 ``
            (v) a prescription for puberty suppression or 
 blocking that is used to normalize puberty in an 
 individual younger than 18 years of age who has been 
 diagnosed with precocious puberty;
 ``
            (vi) any hormone therapy procedure that is used 
 to stimulate puberty in an individual younger than 18 
 years of age who has been diagnosed with delayed 
 puberty, if the hormones administered through that 
 procedure are--
 ``
            (I) consistent with the biological sex of 
 the individual; and
 ``
            (II) used to stimulate a normal puberty 
 consistent with the biological sex of the 
 individual; or
 ``
            (vii) male circumcision.
 ``

    (2) Subject to paragraph

    (3) , and notwithstanding any other 
provision of law or regulation, a contract under this chapter may not 
include coverage for any gender-affirming care or service for any 
individual younger than 18 years of age.
 ``

    (3) In the case of an individual who, as of the effective date of 
this subsection, is younger than 18 years of age and who, as of that 
effective date, is undergoing hormone therapy that, as of the day 
before that effective date, is covered by a contract under this 
chapter, that hormone therapy may continue to be covered under such a 
contract after that effective date if the hormone therapy is provided 
pursuant to a reduction schedule that--
 ``
        (A) is supervised by a physician; and
 ``
        (B) requires that therapy to conclude not later than 1 
 year after that effective date.''.

    (b) Applicability.--The amendment made by subsection

    (a) shall 
apply with respect to any contract entered into, or renewed for a 
contract year, on or after the date of enactment of this Act.
 <all>